Core Insights - New data from the ALPHAMEDIX-02 phase 2 study supports the first-in-class potential of AlphaMedix (212Pb-DOTAMTATE) for treating advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) [1][5][10] - The study demonstrated significant efficacy in both radioligand therapy (RLT)-naïve and RLT-exposed patients, indicating its potential to address unmet medical needs in this challenging cancer type [2][5][10] Study Overview - ALPHAMEDIX-02 is a phase 2, open-label, multicenter study assessing the efficacy and safety of AlphaMedix in patients with unresectable or metastatic SSTR+ GEP-NETs, including cohorts for RLT-naïve and RLT-exposed patients [3][12] - The primary efficacy endpoint was the overall response rate (ORR), with secondary endpoints including progression-free survival (PFS) and overall survival (OS) [3][12] Efficacy Results - In the RLT-naïve cohort (n=35), the ORR was 60.0% per investigator assessment and 57.1% per independent assessment, with a disease control rate (DCR) of 94.3% [4][6] - In the RLT-exposed cohort (n=26), the ORR was 34.6% per investigator assessment and 19.2% per independent assessment, with a DCR of 96.2% [6] - The 36-month PFS rate for RLT-naïve patients was 72.3%, while the 18-month PFS rate for RLT-exposed patients was 82.6% [6] Safety Profile - AlphaMedix exhibited a similar safety profile across both cohorts, with 85.7% of RLT-naïve patients and 84.6% of RLT-exposed patients completing all four doses [6][10] - Treatment-emergent adverse events (TEAEs) were reported in all patients, with grade ≥3 TEAEs occurring in 42.3% of RLT-exposed and 54.3% of RLT-naïve patients, primarily involving lymphocyte count decrease [6][10] Future Development - The positive results from the ALPHAMEDIX-02 study will inform further discussions with health authorities and support the planning of an international phase 3 study [10][11] - Sanofi has entered an exclusive licensing agreement with Orano Med and RadioMedix to globally commercialize AlphaMedix, indicating strong commercial interest and potential market impact [11]

Core Insights - AlphaMedix™ (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in the ALPHAMEDIX-02 phase 2 study, demonstrating significant clinical benefits for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) [1][2][6] - The study showed clinically meaningful overall response rates (ORR) and prolonged clinical benefits in both peptide receptor radionuclide therapy (PRRT)-naïve and PRRT-exposed patients [1][2][6] - AlphaMedix™ has a manageable safety profile, consistent across both patient cohorts [1][3] Study Details - The ALPHAMEDIX-02 study is a phase 2, open-label, multicenter trial evaluating the efficacy and safety of AlphaMedix™ in patients with unresectable or metastatic GEP-NETs [4] - The study included two cohorts: 35 PRRT-naïve patients and 26 PRRT-exposed patients, with the latter having progressive disease after receiving up to four doses of 177Lu-DOTATATE [4] - AlphaMedix™ was administered at a dosage of 67.6 μCi/kg every eight weeks for up to four cycles, with primary endpoints including ORR and safety, and secondary endpoints including progression-free survival (PFS) and overall survival (OS) [4] Industry Context - The results from the ALPHAMEDIX-02 study highlight the potential of lead-212-based radiopharmaceuticals in addressing unmet medical needs for patients with GEP-NETs [2][3] - AlphaMedix™ was granted Breakthrough Therapy Designation by the FDA in February 2024, recognizing its potential clinical benefits for PRRT-naïve patients with unresectable or metastatic GEP-NETs [2] - The study results will be presented at the 2025 European Society for Medical Oncology (ESMO) Congress and will inform discussions with health authorities regarding future regulatory approvals [3][6] Company Background - Orano Med is a clinical-stage biotechnology company focused on developing targeted therapies against cancer using lead-212, an alpha-emitting radioisotope [8] - Sanofi is an R&D-driven biopharma company committed to improving healthcare through innovative therapies, including those for difficult-to-treat cancers [9]

Core Insights - AlphaMedix (Pb-DOTAMTATE) achieved all primary efficacy endpoints in the ALPHAMEDIX-02 phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) [1][2][6] - The study showed significant overall response rates (ORR) and prolonged clinical benefits in both peptide receptor radionuclide therapy (PRRT)-naïve and PRRT-exposed patients [1][2][6] - AlphaMedix has a manageable safety profile, consistent across both patient cohorts [1][3] Study Details - The ALPHAMEDIX-02 study is a phase 2, open-label, multicenter trial evaluating the efficacy and safety of AlphaMedix in patients with unresectable or metastatic GEP-NETs [4] - The study included two cohorts: PRRT-naïve (n=35) and PRRT-exposed (n=26) patients, with AlphaMedix administered at 67.6 μCi/kg every eight weeks for up to four cycles [4] - Primary endpoints included ORR per RECIST1.1 and safety, while secondary endpoints included progression-free survival (PFS) and overall survival (OS) [4] Industry Context - The results from the ALPHAMEDIX-02 study highlight the potential of lead-212-based radiopharmaceuticals in addressing unmet needs for patients with GEP-NETs [2][3] - Alpha-emitters are being studied for their targeted tumor activity and reduced exposure to surrounding healthy tissue, which could represent a significant advancement over current therapies [2] - The study's findings will inform future discussions with health authorities regarding the potential approval and commercialization of AlphaMedix [3][6]

Core Insights - Molecular Partners AG is making significant progress in its clinical programs, particularly with MP0712 and MP0533, with key milestones expected in the near future [2][6] - The company has appointed Martin Steegmaier, Ph.D., as Chief Scientific Officer, enhancing its leadership team [2][15] - Financially, the company is in a strong position with cash reserves projected to last until 2028 [2][19] Research & Development Highlights - MP0533 is in a Phase 1/2a trial for acute myeloid leukemia, showing promising results with over 30% of evaluable patients achieving a clinical response [3][4] - The dosing regimen for MP0533 has been optimized to enhance patient responses, with initial data from cohort 9 expected in Q4 2025 [5][6] - MP0712, a Radio-DARPin therapy for small cell lung cancer, is preparing for an IND filing, with initial clinical data anticipated in H1 2026 [8][9] Corporate Governance Highlights - The appointment of Martin Steegmaier, Ph.D., as CSO is aimed at strengthening the company's focus on oncology drug development [15] - A strategic review led to a planned reduction of up to 40 positions, which is expected to improve operational efficiency and extend the cash runway into 2028 [16] Financial and Business Outlook - For 2025, the company expects total operating expenses between CHF 55-65 million, with a significant portion being non-cash costs [18] - As of June 30, 2025, cash and cash equivalents totaled CHF 114 million, sufficient to fund operations into 2028 [19]

Core Insights - Molecular Partners AG is advancing its clinical programs and expects to achieve key milestones in 2025, including the IND filing and initial clinical data for its lead program MP0712 [2][5][8] - The company has a strong financial position with cash reserves of CHF 131 million as of March 31, 2025, which is projected to fund operations well into 2027 [19] Research & Development Highlights - The strategic partnership with Orano Med has been expanded to co-develop up to ten Pb-labeled radiotherapy programs, including MP0712 targeting DLL3 for small cell lung cancer [3][8] - Preclinical data for MP0712 presented at the AACR 2025 showed high tumor uptake and a favorable toxicity profile, supporting its efficacy in mouse models [4][9] - The IND application for MP0712 is planned for mid-2025, with a Phase 1 dose-escalation study set to begin in the second half of 2025 [5][8] - The second RDT program targeting MSLN is also in development, with promising preclinical data indicating effective binding despite high shedding of MSLN [7][9] Clinical Programs - MP0533, a multispecific T cell engager, is in a Phase 1/2a trial for acute myeloid leukemia, with recent data showing increased response rates in cohort 8 [10][11] - The study protocol for MP0533 has been amended to enhance exposure and response rates, with additional data expected in 2025 [12] - The Switch-DARPin platform aims to improve T cell engagers' safety and potency, with preclinical proof-of-concept data presented at AACR 2025 [13] Financial and Business Outlook - The company anticipates total operating expenses of CHF 55-65 million for 2025, with a portion allocated to non-cash effective costs [18] - The current cash position is expected to support operational needs and capital expenditures through 2027 [19] Corporate Governance Highlights - All motions proposed by the Board of Directors at the Annual General Meeting in April 2025 were approved by shareholders [17]

Core Insights - Molecular Partners AG presented three posters at the AACR Annual Meeting 2025, showcasing advancements in their DARPin therapeutics, particularly in the context of small cell lung cancer and solid tumors [1][2][8] Group 1: Radio-DARPin Programs - The first poster highlighted positive IND-enabling data for MP0712, a Radio-DARPin targeting DLL3, which is on track to provide initial clinical data in the second half of 2025 [1][2][8] - The second poster presented initial preclinical data on a Pb-based Radio-DARPin targeting mesothelin (MSLN), indicating substantial uptake in MSLN-positive tumors with limited accumulation in other organs [1][2][4] - MP0712 demonstrated high tumor uptake and a favorable safety profile in mouse models, with efficacy and tumor reduction correlating with DLL3 expression levels [3][4] Group 2: T Cell Engager Program - The third poster included preclinical proof-of-concept data on a logic-gated CD3 Switch-DARPin T cell engager, which activates T cells specifically in the presence of tumor-associated antigens, enhancing tumor specificity [5][8] - The Switch-DARPin approach allows for CD2 co-stimulation, leading to sustained T cell activation and preventing dysfunction, with significant tumor regression observed in mouse models [5][8] Group 3: Strategic Partnerships - Molecular Partners is co-developing the Radio-DARPin programs with Orano Med, emphasizing the strategic partnership's role in advancing their therapeutic innovations [2][8] - The company is leveraging the unique properties of DARPins to selectively bind to tumor targets while minimizing off-target effects, particularly in the context of MSLN-targeted therapies [4][8]